Moving Oral SERDs into the Adjuvant Setting: Insights from the lidERA Trial with Drs. Mchayleh & Jhaveri

Drs. Wassim Mchayleh and Komal Jhaveri review the phase 3 lidERA trial, which evaluated the oral SERD giredestrant versus standard endocrine therapy in patients with early-stage ER-positive breast cancer. The study demonstrated improved invasive disease–free survival with giredestrant and a favorable safety profile, introducing the first potential new endocrine therapy option in early breast cancer in nearly two decades. They also explore patient selection, toxicity considerations, and how giredestrant might fit alongside CDK4/6 inhibitor–based strategies.